HKSE - Delayed Quote HKD
FUSEN PHARM (1652.HK)
0.260
+0.005
+(1.96%)
At close: 2:17:15 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
565,608
565,608
491,757
385,664
486,854
Cost of Revenue
266,102
266,102
266,736
174,531
220,787
Gross Profit
299,506
299,506
225,021
211,133
266,067
Operating Expense
271,455
271,455
186,414
146,646
181,830
Operating Income
28,051
28,051
38,607
64,487
84,237
Net Non Operating Interest Income Expense
-12,159
-12,159
-10,410
-5,686
-8,005
Pretax Income
-29,448
-29,448
-30,993
23,791
78,405
Tax Provision
6,847
6,847
3,661
7,178
15,737
Net Income Common Stockholders
-36,277
-36,277
-34,605
16,645
70,131
Diluted NI Available to Com Stockholders
-36,277
-36,277
-34,605
16,645
70,131
Basic EPS
-0.05
--
-0.05
0.02
0.09
Diluted EPS
-0.05
--
-0.05
0.02
0.09
Basic Average Shares
752,056
--
756,074
769,622
786,075
Diluted Average Shares
752,056
--
756,074
770,313
790,163
Total Operating Income as Reported
20,016
20,016
43,758
52,137
61,883
Total Expenses
537,557
537,557
453,150
321,177
402,617
Net Income from Continuing & Discontinued Operation
-36,277
-36,277
-34,605
16,645
70,131
Normalized Income
-17,466.250
-17,466.250
-8,843.250
38,303.140
110,835.787
Interest Income
424
424
1,972
2,558
1,429
Interest Expense
12,583
12,583
12,382
8,244
9,434
Net Interest Income
-12,159
-12,159
-10,410
-5,686
-8,005
EBIT
-16,865
-16,865
-18,611
32,035
87,839
EBITDA
18,933
18,933
15,550
55,820
110,296
Reconciled Cost of Revenue
266,102
266,102
266,736
174,531
220,787
Reconciled Depreciation
35,798
35,798
34,161
23,785
22,457
Net Income from Continuing Operation Net Minority Interest
-36,277
-36,277
-34,605
16,645
70,131
Total Unusual Items Excluding Goodwill
-25,081
-25,081
-34,349
-31,016
-22,613
Total Unusual Items
-25,081
-25,081
-34,349
-31,016
24
Normalized EBITDA
44,014
44,014
49,899
86,836
110,272
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-6,270.250
-6,270.250
-8,587.250
-9,357.860
-4,545.213
12/31/2020 - 7/11/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade